Pancreatic Cancer Research

ResearcherPeople’s Hospital of RizhaoActive in the last 2 years

Xiufeng Zhang

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0001-6707-3958; OpenAlex author ID A5077986501. Sources: OpenAlex.

Their work

Papers
3
Trials
0
Grants
0
Labs led
0
Collaborators
16
Papers, trials and grants by year

2019: 1 paper · 2020: none · 2021: none · 2022: none · 2023: 1 paper · 2024: 1 paper

Papers 3

  1. CD64+ fibroblast-targeted vilanterol and a STING agonist augment CLDN18.2 BiTEs efficacy against pancreatic cancer by reducing desmoplasia and enriching stem-l… Co-author DOI 10.1136/gutjnl-2024-332371↗
  2. Irbesartan overcomes gemcitabine resistance in pancreatic cancer by suppressing stemness and iron metabolism via inhibition of the Hippo/YAP1/c-Jun axis. Co-author DOI 10.1186/s13046-023-02671-8↗
  3. SNHG14 enhances gemcitabine resistance by sponging miR-101 to stimulate cell autophagy in pancreatic cancer. Co-author DOI 10.1016/j.bbrc.2019.01.109↗

Closest collaborators

The 16 strongest of 16 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Chongbiao Huang · 2 shared papers, 2023–2024 · strength 0.29
  2. Xiuchao Wang · 2 shared papers, 2023–2024 · strength 0.29
  3. Song Gao · 2 shared papers, 2023–2024 · strength 0.29
  4. Tiansuo Zhao · 2 shared papers, 2023–2024 · strength 0.29
  5. Wenna Jiang · 2 shared papers, 2023–2024 · strength 0.29
  6. Yongjie Xie · 2 shared papers, 2023–2024 · strength 0.29
  7. Tianxing Zhou · 2 shared papers, 2023–2024 · strength 0.29
  8. Jing Liu · 2 shared papers, 2023–2024 · strength 0.29
  9. Jihui Hao · 2 shared papers, 2023–2024 · strength 0.29
  10. Li Lin · 1 shared paper, 2024 · strength 0.16
  11. Yiping Zou · 1 shared paper, 2024 · strength 0.16
  12. Jun Yu · 1 shared paper, 2024 · strength 0.16
  13. Ben-Ru Xin · 1 shared paper, 2019 · strength 0.14
  14. Shengyu Yang · 1 shared paper, 2023 · strength 0.13
  15. Danqi Fu · 1 shared paper, 2023 · strength 0.13
  16. Quan Man · 1 shared paper, 2023 · strength 0.13

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.